-The Hindu The CSO has been consistent with its methods, allowing little room for suspicion of window dressing. Did demonetisation deal a knock-out punch to the Indian economy? Or was it just a mild tap from which it is already recovering? This debate should have been settled with the latest second advance estimates from the Central Statistics Office (CSO) which peg FY17 GDP growth at 7.1%. But commentators who believe that the economy...
More »SEARCH RESULT
Total Matching Records found : 15713
Making a MEAl
-The Indian Express The Aadhaar is no solution to the problems of the Midday MEAl Scheme The Aadhaar scheme was initiated by the UPA government about seven years ago. But it is to the credit of the current Narendra Modi-led government that it saw the potential of Aadhar as an enabler of Direct Benefit Transfer (DBT) schemes and used it for the dispersal of subsidies. But the government has got it wrong...
More »Aadhaar Order on Mid-Day MEAl Denounced as 'Attack On Children's Right to Food'
-TheWire.in The Right to Food Campaign responds to the HRD ministry’s recent mandate on linking Aadhaar with the mid-day MEAl scheme. New Delhi: According to a notification issued by the human resource development ministry last week, children at schools across the country will now be required to either register or have an Aadhaar number in order to avail of the government’s mid-day MEAl scheme. Additionally, as per the government’s notification, any cooks or...
More »There Is A Place For Aadhaar, But The Mid Day MEAl Is Not It -Rukmini S
-HuffingtonPost.in This is a way to force Aadhaar enrolment, not fix the scheme. Children will suffer. I am not usually an opponent of Aadhaar, India's controversial scheme to give a unique identification number to all residents of India, with their biometric information seeded into it. Any fears that I may have about privacy or surveillance or misuse are overridden by my experience that what the poor want is to be counted, not...
More »The high price of Big Pharma greed -Leena Menghaney
-The Hindu In 2014, an Indian pharmaceutical company was globally the first to receive approval to market a biosimilar, thereby affordable version, of the breast cancer drug Trastuzumab. Almost immediately, Swiss pharmaceutical company Roche, innovator of the drug, filed a suit against the Indian Food & Drug Administration (FDA) to block its sale. The action firmly put their profits ahead of the lives of women with breast cancer. Roche effectively embroiled India’s...
More »
